Carvedilol
Carvedilol is a medicine taken by mouth that the FDA label describes as an alpha-/beta-adrenergic blocking agent. The label read, for Coreg, lists three uses: mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, to increase survival and reduce the risk of hospitalization; reducing cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and whose left ventricular ejection fraction is 40% or less, with or without symptoms of heart failure; and essential hypertension.
Also called Coreg
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 20352; UNII 0K47UL67F2. MeSH descriptor D000077261 is Carvedilol. Class: beta-Adrenergic Blocker (FDA established pharmacologic class, RxClass). The label read is the Waylis Therapeutics LLC label for COREG (carvedilol), application NDA020297, effective 2026-07-31 in openFDA. Coreg CR (carvedilol phosphate extended-release capsules) has its own label, which was not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 10 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 10
- Phase 3 or 4
- 10
- Recruiting
- 3
- Regulatory decisions
- 0
| Phase | Recruiting | Active, not recruiting | Completed | Unknown status | All statuses |
|---|---|---|---|---|---|
| Phase 3 | 1 | 0 | 1 | 0 | 2 |
| Phase 4 | 2 | 1 | 2 | 3 | 8 |
| All phases | 3 | 1 | 3 | 3 | 10 |
Conditions these trials study
- Heart failure
- Arrhythmia (heart rhythm problems)
- Heart attack (myocardial infarction)
- Acute coronary syndrome
- Angina pectoris
- Cardiomyopathy (heart muscle disease)
- Chronic kidney disease (CKD)
- Heart failure with mildly reduced or preserved ejection fraction
- Heart failure with reduced ejection fraction (HFrEF)
- Hypertension (high blood pressure)
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- Not reported
Claims and evidence
Context People for whom the US label of carvedilol (Coreg) lists an indication: chronic heart failure, survivors of the acute phase of a myocardial infarction whose left ventricular ejection fraction is 40% or less, essential hypertension
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The label does not state an age range in the passages read.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
- Included
- Patients with mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin
- Clinically stable patients who have survived the acute phase of a myocardial infarction and whose left ventricular ejection fraction is 40% or less, with or without symptomatic heart failure
- Patients with essential hypertension
- Excluded
- None stated
The US label of COREG (carvedilol), in the Waylis Therapeutics LLC version dated 2026-07-31 in openFDA, lists the medicine for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin; for reducing cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and whose left ventricular ejection fraction is 40% or less, with or without symptomatic heart failure; and for the management of essential hypertension.
Applies to Recipient not specified People for whom the US label of carvedilol (Coreg) lists an indication: chronic heart failure, survivors of the acute phase of a myocardial infarction whose left ventricular ejection fraction is 40% or less, essential hypertension
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-08
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1. INDICATIONS AND USAGE
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2026-07-31
- Source state
- Current
- Version fingerprint
654e7c2cc0766a1ae7b9072a509447d9ba3519185a297787af7f8e5f1f3b2741- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260731.
- Retrieved
- Source effective date
- 2026-07-31
- Source state
- Current
- Version fingerprint
654e7c2cc0766a1ae7b9072a509447d9ba3519185a297787af7f8e5f1f3b2741- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
COREG
No label from the application holder was found in the openFDA label dataset for application NDA020297. This page does not show another labeler's label in its place.
COREG CR
No label from the application holder was found in the openFDA label dataset for application NDA022012. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists mild-to-severe chronic heart failure as an indication: Heart failure
Applies to Recipient not specified People for whom the US label of carvedilol (Coreg) lists an indication: chronic heart failure, survivors of the acute phase of a myocardial infarction whose left ventricular ejection fraction is 40% or less, essential hypertension
The US label of COREG (carvedilol), in the Waylis Therapeutics LLC version dated 2026-07-31 in openFDA, lists the medicine for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin; for reducing cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and whose left ventricular ejection fraction is 40% or less, with or without symptomatic heart failure; and for the management of essential hypertension.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists reducing cardiovascular mortality after the acute phase of a myocardial infarction, when the left ventricular ejection fraction is 40% or less, as an indication: Heart attack (myocardial infarction)
Applies to Recipient not specified People for whom the US label of carvedilol (Coreg) lists an indication: chronic heart failure, survivors of the acute phase of a myocardial infarction whose left ventricular ejection fraction is 40% or less, essential hypertension
The US label of COREG (carvedilol), in the Waylis Therapeutics LLC version dated 2026-07-31 in openFDA, lists the medicine for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin; for reducing cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and whose left ventricular ejection fraction is 40% or less, with or without symptomatic heart failure; and for the management of essential hypertension.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists essential hypertension as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified People for whom the US label of carvedilol (Coreg) lists an indication: chronic heart failure, survivors of the acute phase of a myocardial infarction whose left ventricular ejection fraction is 40% or less, essential hypertension
The US label of COREG (carvedilol), in the Waylis Therapeutics LLC version dated 2026-07-31 in openFDA, lists the medicine for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin; for reducing cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and whose left ventricular ejection fraction is 40% or less, with or without symptomatic heart failure; and for the management of essential hypertension.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 2
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 6 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 10
Record details
- Record id
cardio:carvedilol- Content hash
263314c1f56a704cd2b19b752ba8aae69e48e764c5649b869b574116e50ea0ad